(News Bulletin 247) – Invest Securities confirms this morning its buy rating on the TME Pharma share, with an unchanged price target of 4.2 euros.
The recommendation comes as the company this morning released 15-month median overall survival data from its glioblastoma expansion study evaluating the NOX-A12/radiotherapy/bevacizumab tricombination.
‘At this stage, 5 out of 6 patients in the cohort are still alive, compared with known data for the same patient profile, which show a median overall survival of 9.7 months with standard care treatments. Although on a small cohort, these results become extremely promising,’ stresses Invest.
The broker says that depending on upcoming data and ongoing discussions with the FDA, a Ph II study of PoC could be launched in the near term, with the potential to pave the way for accelerated approval.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
